CAAP Company: Tecla Featured in a BELL Paralympics TV Commercial
Former OBIO CAAP Company Tecla is in the news again! This time featured in a BELL
Paralympics TV Commercial.
This commercial highlights the integration of everyday tech and assistive devices, we love the private cat too!
View the commercial here
OBIO CEO Gail Garland Provides Opening Remarks at MDCC's Strategic Entry into the U.S. MedTech Market Seminar
OBIO CEO Gail Garland was asked by MDCC to provide opening remarks at their hotly anticipated Strategic Entry into the U.S. MedTech Market for Canadian Firms Seminar.
The Greater MSP and MDCC brought to Toronto 4 world-class experts with backgrounds in finance, reimbursement, talent management and the FDA. Each shared their insights and tools for success for strategically entering into the U.S. MedTech market.
New Study Provides Further Evidence that Rna Disruption Assay™ (RDA™) May Be Useful Tool In Predicting Clinical Outcome Of Chemotherapy In Breast Cancer Patients
Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute
A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients.
For the full press release, click here
For the Journal Article, click here
Pre-CAAP Company: SensOR Medical Featured at U OF T Engineering’s Entrepreneurship Hatchery Demo Day
Demo Day is the culmination of The Hatchery’s intensive summer program, where student teams work with experienced mentors — including executives, lawyers, medical professionals and engineers — to develop their business ideas and competencies. They receive detailed feedback and guidance on everything from patent applications and incorporation to honing their pitches and building prototypes, which they create using 3D printers and other fabrication resources provided by The Hatchery.
The seed funding at stake at Demo Day includes a grand prize of $20,000 and a runner-up prize of $10,000, donated by alumnus Anthony Lacavera (CompE 9T7), founder and chairman of Globalive Holdings and former CEO of WIND Mobile. An additional $2,500 Orozco prize is provided through funds raised by the students themselves.
For the full article, click here
CAAP Company: Tecla is helping those who live with Multiple Sclerosis
Former OBIO CAAP company Tecla is helping those who live with Multiple Sclerosis, learn about Michael's story today!
Medical Developments International Limited Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada
Sept 11, 2016 Medical Developments International Limited ("MDI") (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in Canada.
Penthrox® is a fast-acting, inhaled, non-narcotic analgesic drug/device combination for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.
For the full press release, click here
Self Care Catalysts: App to Support Self-Management for Primary Biliary Cholangitis (PBC)
September 09, 2016 - Toronto: To celebrate International PBC Day on September 11, 2016, Self Care Catalysts -- a patient intelligence and solutions company -- is announcing its newest self-care mobile app, created to support patients diagnosed with Primary Biliary Cholangitis (PBC). The team at Self Care Catalysts worked closely with the Canadian PBC Society to create a customized suite of self-care tools to support the total care for PBC, and to empower patients to play an active role in tracking their health story -- so that more can be understood about this rare disease.
For the full press release, click here
CAAP Company: Medella Health Wins James Dyson Award
The prize was awarded for their contact lens which could completely change how diabetics monitor their blood sugar.
The lens non-invasively monitors glucose levels and transmits the information to a mobile phone, Harry Gandhi, co-founder of Medella Health, told CBC News. Medella Health won the national prize in the James Dyson Award, a world-renowned design competition with a top national prize of $4,000.
For the full CBC article click here
For the CTV News feature, click here
Pre-CAAP Company: NERv Technologies selected as one of #Top500 Deeptech Startups!
Sept 6, 2016 NERv Technologies was selected as one of the top 500 Deep Tech startups at the upcoming Hello Tomorrow Global Summit in Paris.
Follow their journey on twitter here
OBIO's Very Own - Inspiring the Future at Rotman
OBIO's Dr. Klaus Fiebig, CAAP Senior Director, Strategic Programs was asked to be a panelist on the Rotman School of Management - University of Toronto - Start-up & Entrepreneurs Panel.
Overall, there was a strong buzz in the room with many enthusiastic MBA students evaluating if entrepreneurship and the startup world would be the right fit in their very near future, we certainly hope so!
Pre-CAAP Company: An Interview with TranQool therapist Dawn
Dawn joined TranQool because she felt that people need a platform where they can access counselling and services right at their fingertips.
TranQool enables you to talk with a real therapist in the comfort of your own home. You sign up. are matched with a therapist, have one-on-one video calls and build on your progress with assignments.
For the interview click here
100 Brains + 50 Locations = The Brain Project
100 brains, 50 locations all for 1 important cause: Brain Health!
The art installations can be found across Toronto and highlight the importance of brain health with the aim to improve the quality of life for those with dementia and other neurological disorders.
The project is being delivered by the Baycrest Foundation who see the project as a"catalyst for discussion and awareness of brain health."
Learn more here
Find a Brain Installation here
OBIO is Golden Horseshoe Bound
OBIO was invited to McMaster University by Susan Searls Giroux, Assistant Vice-President of McMaster University for a day filled with science, bus and partnerships.
The day started with a tour of the Biointerfaces Institute with the impressive John Brennan, Director of the Biointerfaces Institute. The discussion during the tour focused on diagnostics, cell therapies and biointerfaces and what the current and future needs will be for companies.
Pre-CAAP Company: AKIRA MD Featured in Metro
Pre-CAAP Company: Pathcore makes it to 43North Semi-Finals
Pathcore Heading South to 43North!
OBIO Pre-CAAP Company Pathcore has made it to the 43North semi-finals in Buffalo this fall!
Every year 43North awards $5 MILLION in capital, including a grand prize of $1 Million, to truly remarkable startups from around the world.
Learn more here
MaRS announces program to facilitate the development and procurement of breakthrough health technologies in Ontario
Innovation Partnership: Procurement by Co-Design is a unique program that offers healthcare-service providers something rare: the opportunity to participate in the development of technology tailor-made for them—solutions that address the particular problems they often face—and then actually procure these solutions.
For more information click here
CAAP Company: ScarX announces approval for trial of first clinically-promising scar reduction cream
Aug 18, 2016 - Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.
For the full press release click here
Zymeworks’ ZW25 and ZW33 Granted Orphan Drug Designation for Ovarian Cancer by FDA
Aug 18, 2016 - Vancouver - Zymeworks Inc., a biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics, including bi-specific antibodies and drug conjugates for the treatment of cancer, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zymeworks’ lead investigational products ZW25 and ZW33 for the treatment of ovarian cancer.
For the full press release, click here
Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
Aug 17, 2016 TORONTO - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621 (SIRPaFc), in solid tumors and mycosis fungoides.
For the full press release, click here
Profound Medical Appoints Arun Menawat as CEO
Aug 15, 2016 - Toronto: Profound Medical Corp. (TSXV:PRN), an emerging medical device company focused on prostate cancer care, today announced the appointment of Arun Menawat, Ph.D. as its new Chief Executive Officer. Steven Plymale, the Company’s current CEO, will transition to President and Chief Operating Officer.
For the full press release, click here